登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《bioRxiv，6月20日，Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-06-22

  • Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

    View ORCID ProfileSimon P Graham, View ORCID ProfileRebecca K McLean, View ORCID ProfileAlexandra J Spencer, View ORCID ProfileSandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, Jane C Edwards, Jack W P Hayes, Veronica Martini, Nazia Thakur,

    doi: https://doi.org/10.1101/2020.06.20.159715

    Abstract

    Clinical development of the COVID-19 vaccine candidate ChAdOx1 nCoV-19, a replication-deficient simian adenoviral vector expressing the full-length SARS-CoV-2 spike (S) protein was initiated in April 2020 following non-human primate studies using a single immunisation. Here, we compared the immunogenicity of one or two doses of ChAdOx1 nCoV-19 in both mice and pigs. Whilst a single dose induced antigen-specific antibody and T cells responses, a booster immunisation enhanced antibody responses, particularly in pigs, with a significant increase in SARS-CoV-2 neutralising titres.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.06.20.159715v1
50浏览量
原文链接
相关报告

  • 《6月21日_带有复制缺陷型病毒载体的COVID-19候选疫苗ChAdOx1 nCoV-19的初次加强免疫接种的免疫原性评估》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-23
    • 1.时间：2020年6月20日 2.机构或团队：英国Pirbright研究所、牛津大学、悉尼大学、哈维尔研究中心、罗瑟琳富兰克林研究中心、英国公共卫生部门 3.事件概要 英国Pirbright研究所，牛津大学，悉尼大学，哈维尔研究中心，罗瑟琳富兰克林研究中心和英国公共卫生部门的科研人员在bioRxiv预印本平台发表题为“Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19”的文章。 文章指出，2020年4月开始在非人灵长类动物中临床开发一种单一使用的CoVID-19候选疫苗ChAdOx1 nCoV-19，这是一种带有复制缺陷型猿猴腺病毒载体的表达完整的SARS-CoV-2 刺突蛋白。本文中，研究人员比较了一剂或两剂ChAdOx1 nCoV-19在小鼠和猪中的免疫原性。虽然单剂量可以诱导抗原特异性抗体和T细胞反应，但增多疫苗的剂量能增强抗体反应，这在猪体内尤为明显，SARS-CoV-2的中和滴度显著增加。 *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用。 4.附件： 原文链接：https://www.biorxiv.org/content/10.1101/2020.06.20.159715v1
    34浏览量
    原文链接

  • 《Nature，7月30日，ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-08-18
    • ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques Neeltje van Doremalen, Teresa Lambe, […]Vincent J. Munster Nature (2020) Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 20191,2 and is responsible for the COVID-19 pandemic3. Vaccines are an essential countermeasure urgently needed to control the pandemic4. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was predominantly Th1, as demonstrated by IgG subclass and cytokine expression profiling. Vaccination with ChAdOx1 nCoV-19 (prime-only and prime-boost regimen) induced a balanced Th1/Th2 humoral and cellular immune response in rhesus macaques. We observed a significantly reduced viral load in bronchoalveolar lavage fluid and lower respiratory tract tissue of vaccinated rhesus macaques challenged with SARS-CoV-2 compared with control animals, and no pneumonia was observed in vaccinated animals. However, there was no difference in nasal shedding between vaccinated and control animals. Importantly, no evidence of immune-enhanced disease following viral challenge in vaccinated animals was observed. Safety, immunogenicity and efficacy of ChAdOx1 nCoV-19 against symptomatic PCR-positive COVID-19 disease will now be assessed in randomised controlled human clinical trials.
    78浏览量
    原文链接